Level Biotechnology Overview
Get informed when a big investor buys or sells
+ Follow14.09%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for 3118.TWO is 14.09%. That is above the Healthcare sector average of -100.59%. Investors often review this figure alongside Level Biotechnology's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, 3118.TWO currently prints 14.09% for ROE, while the sector average sits near -100.59%. That is roughly 114.0% above the sector mean. Large gaps often invite a closer look at Level Biotechnology's growth, margins, and balance sheet.
Return on Equity shows how effectively Level Biotechnology converts resources into returns. At 14.09%, 3118.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting 3118.TWO's ROE (14.09%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Level Biotechnology's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
